share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q：2024財年三季報
美股SEC公告 ·  2024/11/13 05:08

Moomoo AI 已提取核心訊息

GeoVax Labs reported Q3 2024 financial results, with revenue of $2.8 million primarily from the BARDA contract for COVID-19 vaccine development, compared to no revenue in Q3 2023. Net loss narrowed to $5.8 million from $8.4 million year-over-year. Research and development expenses increased 6.5% to $7.4 million, while general and administrative costs decreased 24.9% to $1.2 million.The company's cash position strengthened to $8.6 million as of September 30, 2024, up from $6.5 million at year-end 2023, bolstered by approximately $19.1 million in net proceeds from equity offerings and warrant exercises. The BARDA contract, valued at up to $45 million, will fund manufacturing and support for a 10,000-participant Phase 2b trial of GEO-CM04S1 COVID-19 vaccine.Management believes current cash reserves will fund operations into Q1 2025. Key clinical programs include GEO-CM04S1 in multiple Phase 2 trials for COVID-19 prevention and Gedeptin for advanced head and neck cancer, which is advancing toward an expanded Phase 2 trial planned for first half of 2025.
GeoVax Labs reported Q3 2024 financial results, with revenue of $2.8 million primarily from the BARDA contract for COVID-19 vaccine development, compared to no revenue in Q3 2023. Net loss narrowed to $5.8 million from $8.4 million year-over-year. Research and development expenses increased 6.5% to $7.4 million, while general and administrative costs decreased 24.9% to $1.2 million.The company's cash position strengthened to $8.6 million as of September 30, 2024, up from $6.5 million at year-end 2023, bolstered by approximately $19.1 million in net proceeds from equity offerings and warrant exercises. The BARDA contract, valued at up to $45 million, will fund manufacturing and support for a 10,000-participant Phase 2b trial of GEO-CM04S1 COVID-19 vaccine.Management believes current cash reserves will fund operations into Q1 2025. Key clinical programs include GEO-CM04S1 in multiple Phase 2 trials for COVID-19 prevention and Gedeptin for advanced head and neck cancer, which is advancing toward an expanded Phase 2 trial planned for first half of 2025.
GeoVax Labs公佈了2024年第三季度的財務結果，營業收入爲280萬美元，主要來自BARDA合同下的COVID-19生物-疫苗開發，而2023年第三季度沒有收入。淨虧損從去年同期的840萬美元縮小至580萬美元。研究與開發費用增加了6.5%，達到740萬美元，而一般及行政支出減少了24.9%，降至120萬美元。截至2024年9月30日，公司現金狀況增強，達到860萬美元，比2023年年末的650萬美元有所增加，這得益於約1910萬美元的股票發行和認股權證行使的淨收入。BARDA合同的價值最高可達4500萬美元，將用於資助製造業及支持一項有10000名參與者的GEO-CM04S1 COV...展開全部
GeoVax Labs公佈了2024年第三季度的財務結果，營業收入爲280萬美元，主要來自BARDA合同下的COVID-19生物-疫苗開發，而2023年第三季度沒有收入。淨虧損從去年同期的840萬美元縮小至580萬美元。研究與開發費用增加了6.5%，達到740萬美元，而一般及行政支出減少了24.9%，降至120萬美元。截至2024年9月30日，公司現金狀況增強，達到860萬美元，比2023年年末的650萬美元有所增加，這得益於約1910萬美元的股票發行和認股權證行使的淨收入。BARDA合同的價值最高可達4500萬美元，將用於資助製造業及支持一項有10000名參與者的GEO-CM04S1 COVID-19生物-疫苗的20億試驗。管理層相信，當前的現金儲備將能夠支持運營直到2025年第一季度。關鍵臨牀項目包括GEO-CM04S1在多個階段2試驗中進行COVID-19預防，以及Gedeptin用於晚期頭頸癌，後者正向計劃於2025年上半年進行的擴展階段2試驗推進。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Organovo Holdings
    ONVO
    -- 1.270
    Silexion Therapeutics
    SLXN
    -- 1.230
    LAVA Therapeutics
    LVTX
    -- 1.340
    Dominari Holdings
    DOMH
    -- 9.900
    GT Biopharma
    GTBP
    -- 2.4600
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股集體大漲！2025年中國資產前景如何？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家機構唱好中國資產。 $阿里巴巴 (BABA.US)$ 第三財季總營收同比增長8%，AI助推阿裏雲收入大漲13%。 🎙️討論： 1. 阿裏巴巴Q3單季報發布後股價飆升。此時是否是入場良 展开
    中國股票的瘋狂反彈暫停了？華爾街仍然對熱門股下注